SFOSF
Price
$2.78
Change
-$0.00 (-0.00%)
Updated
Jan 13 closing price
Capitalization
10.11B
Intraday BUY SELL Signals
SGIOF
Price
$18.00
Change
+$2.79 (+18.34%)
Updated
Jan 7 closing price
Capitalization
15.59B
Intraday BUY SELL Signals
Interact to see
Advertisement

SFOSF vs SGIOF

Header iconSFOSF vs SGIOF Comparison
Open Charts SFOSF vs SGIOFBanner chart's image
Shanghai Fosun Pharmaceutical Group
Price$2.78
Change-$0.00 (-0.00%)
Volume$900
Capitalization10.11B
Shionogi & Co
Price$18.00
Change+$2.79 (+18.34%)
Volume$600
Capitalization15.59B
SFOSF vs SGIOF Comparison Chart in %
SFOSF
Daily Signal:
Gain/Loss:
SGIOF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
SFOSF vs. SGIOF commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SFOSF is a Hold and SGIOF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (SFOSF: $2.78 vs. SGIOF: $18.00)
Brand notoriety: SFOSF and SGIOF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: SFOSF: 69% vs. SGIOF: 83%
Market capitalization -- SFOSF: $10.11B vs. SGIOF: $15.59B
SFOSF [@Pharmaceuticals: Generic] is valued at $10.11B. SGIOF’s [@Pharmaceuticals: Generic] market capitalization is $15.59B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $66.57B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.6B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SFOSF’s FA Score shows that 1 FA rating(s) are green whileSGIOF’s FA Score has 3 green FA rating(s).

  • SFOSF’s FA Score: 1 green, 4 red.
  • SGIOF’s FA Score: 3 green, 2 red.
According to our system of comparison, SGIOF is a better buy in the long-term than SFOSF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SFOSF’s TA Score shows that 3 TA indicator(s) are bullish while SGIOF’s TA Score has 5 bullish TA indicator(s).

  • SFOSF’s TA Score: 3 bullish, 3 bearish.
  • SGIOF’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SGIOF is a better buy in the short-term than SFOSF.

Price Growth

SFOSF (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while SGIOF (@Pharmaceuticals: Generic) price change was +18.34% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.34%. For the same industry, the average monthly price growth was +9.59%, and the average quarterly price growth was +20.08%.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.34% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SGIOF($15.6B) has a higher market cap than SFOSF($10.1B). SFOSF has higher P/E ratio than SGIOF: SFOSF (15.63) vs SGIOF (14.17). SGIOF YTD gains are higher at: 18.343 vs. SFOSF (11.200). SGIOF has higher annual earnings (EBITDA): 234B vs. SFOSF (6.27B). SGIOF has more cash in the bank: 584B vs. SFOSF (13.5B). SGIOF has less debt than SFOSF: SGIOF (22.7B) vs SFOSF (36.7B). SGIOF has higher revenues than SFOSF: SGIOF (437B) vs SFOSF (39.5B).
SFOSFSGIOFSFOSF / SGIOF
Capitalization10.1B15.6B65%
EBITDA6.27B234B3%
Gain YTD11.20018.34361%
P/E Ratio15.6314.17110%
Revenue39.5B437B9%
Total Cash13.5B584B2%
Total Debt36.7B22.7B162%
FUNDAMENTALS RATINGS
SFOSF vs SGIOF: Fundamental Ratings
SFOSF
SGIOF
OUTLOOK RATING
1..100
9848
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
20
Undervalued
PROFIT vs RISK RATING
1..100
10097
SMR RATING
1..100
792
PRICE GROWTH RATING
1..100
5241
P/E GROWTH RATING
1..100
5521
SEASONALITY SCORE
1..100
n/a65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SGIOF's Valuation (20) in the null industry is in the same range as SFOSF (24). This means that SGIOF’s stock grew similarly to SFOSF’s over the last 12 months.

SGIOF's Profit vs Risk Rating (97) in the null industry is in the same range as SFOSF (100). This means that SGIOF’s stock grew similarly to SFOSF’s over the last 12 months.

SGIOF's SMR Rating (2) in the null industry is significantly better than the same rating for SFOSF (79). This means that SGIOF’s stock grew significantly faster than SFOSF’s over the last 12 months.

SGIOF's Price Growth Rating (41) in the null industry is in the same range as SFOSF (52). This means that SGIOF’s stock grew similarly to SFOSF’s over the last 12 months.

SGIOF's P/E Growth Rating (21) in the null industry is somewhat better than the same rating for SFOSF (55). This means that SGIOF’s stock grew somewhat faster than SFOSF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SFOSFSGIOF
RSI
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
57%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
53%
Momentum
ODDS (%)
Bullish Trend 2 days ago
38%
Bullish Trend 2 days ago
57%
MACD
ODDS (%)
Bullish Trend 2 days ago
49%
Bullish Trend 2 days ago
58%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
48%
Bullish Trend 2 days ago
44%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
46%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
53%
View a ticker or compare two or three
Interact to see
Advertisement
SFOSF
Daily Signal:
Gain/Loss:
SGIOF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FTXL145.771.09
+0.75%
First Trust Nasdaq Semiconductor ETF
OIA6.190.04
+0.65%
INVESCO Municipal Income OPPORTUNITIES TRUST
BRLN51.780.03
+0.06%
iShares Floating Rate Loan Active ETF
JEMB53.26-0.04
-0.08%
Janus Henderson Em Mkts Dbt Hrd Ccy ETF
IWMI50.64-0.10
-0.20%
NEOS Russell 2000 High Income ETF

SFOSF and

Correlation & Price change

A.I.dvisor tells us that SFOSF and CANN have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SFOSF and CANN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SFOSF
1D Price
Change %
SFOSF100%
N/A
CANN - SFOSF
21%
Poorly correlated
+3.13%
HCM - SFOSF
21%
Poorly correlated
+0.13%
SGIOF - SFOSF
11%
Poorly correlated
N/A
RAFA - SFOSF
9%
Poorly correlated
N/A
TKPHF - SFOSF
7%
Poorly correlated
N/A
More

SGIOF and

Correlation & Price change

A.I.dvisor tells us that SGIOF and AGYTF have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SGIOF and AGYTF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SGIOF
1D Price
Change %
SGIOF100%
N/A
AGYTF - SGIOF
25%
Poorly correlated
N/A
HLNCF - SGIOF
21%
Poorly correlated
+1.23%
SFOSF - SGIOF
11%
Poorly correlated
N/A
ROMJF - SGIOF
8%
Poorly correlated
+0.30%
TEVJF - SGIOF
8%
Poorly correlated
N/A
More